Clinical and economic analysis of the use of the medicinal product dapagliflozin in patients with chronic heart failure and type 2 diabetes mellitus

Clinical and economic analysis of the use of the medicinal product dapagliflozin in patients with chronic heart failure and type 2 diabetes mellitus

OBJECTIVE: Clinical and economic evaluation of using the dapagliflozin in addition to standard therapy for patients with CHF (Chronic Heart Failure) and concomitant type 2 DM (Diabetes mellitus).MATERIALS AND METHODS: All adult Russian patients with confirmed diagnosis of CVD and concomitant type 2...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Zhuravleva, J. V. Gagarina, T. V. Marin
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2024-07-01
Series:	Сахарный диабет
Subjects:	dapagliflozin heart failure cardiovascular death death from any cause hospitalizations due to chronic heart failure emergency treatment due to chronic heart failure willingness-to-pay threshold
Online Access:	https://www.dia-endojournals.ru/jour/article/view/13147
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and efficacy of SGLT2 inhibitors in heart failure patients with ischemic and non-ischemic etiologies: a systematic review and meta-analyses
by: Hasan Fareed Siddiqui, et al.
Published: (2025-03-01)

2023 Updated European Society of Cardiology guidelines on heart failure
by: A. G. Rakisheva, et al.
Published: (2024-06-01)

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)

The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
by: Skala Mamand Jawhar, et al.
Published: (2023-09-01)

Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2024-08-01)

Ambient Air Pollution Exposure and Adverse Outcomes Among Medicare Beneficiaries With Heart Failure
by: Amgad Mentias, et al.
Published: (2024-08-01)

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
by: Carlos Escobar, et al.
Published: (2025-07-01)

The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure
by: Kenji Nakano, et al.
Published: (2025-06-01)

Role of Heart Rate Recovery in Chronic Heart Failure: Results From the MyoVasc Study
by: David Velmeden, et al.
Published: (2025-05-01)

Effect of dapagliflozin on serum N‐terminal fragment-proB‐type natriuretic peptide level in patient with acute decompensated heart failure
by: Hanna Jassim Dohei, et al.
Published: (2025-03-01)

Dynamics of uric acid concentration against the background of early dapagliflozin use in patients with acute decompensation of heart failure
by: Laura H. Sarieva, et al.
Published: (2024-01-01)

Emotions Experienced by Nurses in the Care of Terminal Heart Failure Patients
by: Marta Polanowska, et al.
Published: (2024-12-01)

DECOMPENSATED CHRONIC HEART FAILURE: FROM PATHOGENESIS TO PROGNOSIS
by: K. S. Fazulina
Published: (2016-12-01)

Effectiveness of sarcopenia screening indicators in predicting death in older patients with chronic heart failure
by: Zhouyu Li, et al.
Published: (2025-06-01)

Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
by: Zehui Jiang, et al.
Published: (2025-05-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness
by: Adarsh Raja, et al.
Published: (2024-12-01)

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure
by: Shodai Kawanami, et al.
Published: (2025-06-01)

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF
by: Andrew P. Ambrosy, et al.
Published: (2025-06-01)

FACTORS EFFECTING THE DECOMPENSATION OF CHRONIC HEART FAILURE IN THE ELDERLY
by: V. N. Larina, et al.
Published: (2015-09-01)

The Role of Structured Telephone Support in the Development of Self-care in Comorbid Patients with Chronic Heart Failure
by: E. D. Kartamysheva, et al.
Published: (2022-11-01)

Remote Heart Failure Patients Telemonitoring: Results of the TreC Heart Failure Study
by: Massimiliano Maines, et al.
Published: (2025-05-01)

SUCCESSFUL HEART TRANSPLANTATION IN PATIENT WITH CRITICAL MULTIORGAN FAILURE
by: L. A. Bockeria, et al.
Published: (2010-03-01)

HEART FAILURE AND DIABETES MELLITUS: SELECTED ISSUES OF ETIOLOGY AND PATHOGENESIS, PROGNOSIS AND TREATMENT
by: B. U. Mardanov, et al.
Published: (2017-01-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Ivabradine therapy and correction of the target organ pathology in patients with ischemic chronic heart failure
by: M. V. Surovtseva, et al.
Published: (2013-06-01)

The results of orthotopic heart transplantation using the bicaval technique
by: B. M. Todurov, et al.
Published: (2023-06-01)

MANAGEMENT OF PATIENTS WITH RHEUMATIC HEART DISEASES AND CHRONIC HEART FAILURE
by: Aleksey Nikolayevich Kalyagin
Published: (2009-09-01)

The effect of hyperuricemia and type 2 diabetes mellitus on the development and course of chronic heart failure
by: M. G. Kolpacheva, et al.
Published: (2025-03-01)

Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure
by: V. V. Davydov, et al.
Published: (2019-04-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

CLINICAL APPROACHES TO INTERPRETATION OF CLINICAL TRAILS RESULTS ON BETA-BLOCKERS FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE
by: S. R. Giljarevskiy, et al.
Published: (2016-01-01)

CLINICAL SIGNIFICANCE OF ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE
by: L. I. Dvoretsky, et al.
Published: (2010-06-01)

Dapagliflozin improves cardiac function and reduces adverse events in myocardial infarction: a meta-analysis in diabetic and non-diabetic populations
by: Shuang Li, et al.
Published: (2025-06-01)

THE SPECIFIC FEATURES OF HEART AND VESSELS REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH LISINOPRIL DURING 6 MONTHS
by: N. A. Kosheleva, et al.
Published: (2016-01-01)

Diagnostic value of AATs to β1- AR in elderly patients with chronic heart failure
by: V. Yu. Zharynova, et al.
Published: (2014-10-01)

A multicentre registry of hospitalized patients with acute and chronic heart failure: Study design of the H2‐registry
by: Johannes Leiner, et al.
Published: (2025-08-01)

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
by: A. A. Shchendrygina, et al.
Published: (2021-07-01)

IRON DEFICIENCY AND ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE
by: N. I. Stuklov
Published: (2017-11-01)